

**Establishment of In-House Facility and Acquisition of License for Packaging,
Labeling and Storage of Regenerative Medicine Products**

SanBio Co, Ltd. (headquarters: Chuo-ku, Tokyo, Representative Director and President: Keita Mori) hereby announces that it has established an in-house facility for packaging, labeling and storage of regenerative medicine products (hereafter, the “Facility”) and that on December 15, 2022, it obtained a license for packaging, labeling and storage of regenerative medicine products.

The Company’s pipeline product SB623 is currently under review by regulatory authorities for approval as a treatment for chronic effects of traumatic brain injury. The Company is in the process of building a distribution network to ensure smooth and seamless delivery of the product to patients after its approval. This includes developing R-SAT[®], a distribution management and administration schedule support system for regenerative medicine products. The Company decided to establish the Facility to flexibly respond to the needs of medical institutions. Following a review of its quality management systems by the regulatory authorities, the Company was granted a license to package, label and store regenerative medicine products at the Facility. This is a significant step in the Company’s ongoing efforts to establish a seamless and efficient distribution network.

Facility overview

Location: Chuo-ku, Tokyo

Size: 54.47m²

Purpose: Packaging, Labeling and Storage of Regenerative Medicine Products

For more information, contact:

SanBio Co., Ltd.

Management Administration

Email: info@sanbio.jp